文献速递甲状腺疾病

慢性肾脏病与甲状腺激素

Chronic Kidney Disease and Thyroid Hormones.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于中国肾脏数据系统的回顾性队列研究纳入30804例慢性肾脏病患者,分析甲状腺功能与临床结局的关联及甲状腺激素替代治疗的效果。甲状腺功能减退独立预测肾衰竭风险增加(校正HR=1.29),甲状腺功能减退和亢进均与全因死亡风险增加相关,甲状腺激素替代治疗与甲状腺功能减退患者肾衰竭风险降低相关(校正HR=0.65)。

要点

  • 甲状腺功能减退独立预测慢性肾脏病患者肾衰竭风险增加(校正HR=1.29)。
  • 甲状腺功能减退和亢进均与慢性肾脏病患者全因死亡风险增加相关。
  • 甲状腺激素替代治疗与甲状腺功能减退患者肾衰竭风险降低相关(校正HR=0.65)。

核心结论

  • 甲状腺功能减退加速慢性肾脏病进展,而甲状腺功能减退和亢进均增加慢性肾脏病患者死亡风险。
  • 甲状腺激素替代治疗似乎减轻甲状腺功能减退对肾功能的不良影响。
  • 作者认为慢性肾脏病管理中应考虑定期监测甲状腺功能和适当的甲状腺激素替代治疗。

研究设计与样本

  • 回顾性队列研究,使用中国肾脏数据系统的数据,纳入30804例慢性肾脏病患者。
  • 主要终点为复合肾衰竭和全因死亡,次要终点为甲状腺激素替代治疗对肾脏结局的影响。
  • 采用多变量Cox比例风险回归模型和Kaplan-Meier生存分析,并校正相关临床和人口学协变量。

主要发现

  • 30804例慢性肾脏病患者中,26673例(86.6%)甲状腺功能正常,2291例(7.4%)甲状腺功能减退,1840例(6.0%)甲状腺功能亢进。
  • 甲状腺功能减退独立预测肾衰竭风险增加(校正HR=1.29;95%CI,1.15-1.45;P<.001)。
  • 甲状腺功能减退(校正HR=1.24;95%CI,1.11-1.39;P<.001)和甲状腺功能亢进(校正HR=1.20;95%CI,1.07-1.33;P<.01)均与全因死亡风险增加相关。
  • 在甲状腺功能减退患者中,甲状腺激素替代治疗与肾衰竭风险显著降低相关(校正HR=0.65;95%CI,0.52-0.82;P<.001)。

临床怎么用

  • 作者认为慢性肾脏病管理中应考虑定期监测甲状腺功能和适当的甲状腺激素替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid dysfunction is prevalent in chronic kidney disease (CKD) patients and significantly impacts renal outcomes and mortality. OBJECTIVE: This study investigated the associations between thyroid function and clinical outcomes, and also the therapeutic effects of thyroid hormone replacement therapy (THRT) in CKD patients. METHODS: We conducted a retrospective cohort study using data from the China Renal Data System. The primary endpoints were composite renal failure and all-cause mortality. The secondary endpoint was the impact of THRT on renal outcomes. Associations were analyzed using multivariable Cox proportional hazards regression models and Kaplan-Meier survival analyses, with adjustment for relevant clinical and demographic covariates. RESULTS: Among 30 804 CKD patients enrolled, 26 673 (86.6%) had normal thyroid function, 2291 (7.4%) had hypothyroidism, and 1840 (6.0%) had hyperthyroidism. Hypothyroidism independently predicted increased risk of renal failure (adjusted HR = 1.29; 95% CI, 1.15-1.45; P < .001). Both hypothyroidism (adjusted HR = 1.24; 95% CI, 1.11-1.39; P < .001) and hyperthyroidism (adjusted HR = 1.20; 95% CI, 1.07-1.33; P < .01) were associated with increased all-cause mortality. Notably, THRT was associated with significantly reduced risk of renal failure (adjusted HR = 0.65; 95% CI, 0.52-0.82; P < .001) in hypothyroid patients. CONCLUSION: This large-scale cohort study demonstrates that hypothyroidism accelerates CKD progression, while both hypo- and hyperthyroidism increase mortality risk in CKD patients. THRT appears to attenuate the adverse effects of hypothyroidism on renal function. Regular thyroid function monitoring and appropriate THRT should be considered in CKD management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Hu H, Li W, et al. Chronic Kidney Disease and Thyroid Hormones. J Clin Endocrinol Metab. 2025. PMID: 39657910. doi:10.1210/clinem/dgae841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。